{"hands_on_practices": [{"introduction": "Managing pregnant transplant recipients involves balancing immunosuppression with the heightened risks of obstetric complications like preeclampsia. Clinicians must be adept at quantifying these risks to weigh the benefits and burdens of preventive therapies. This exercise challenges you to apply core epidemiological principles, specifically the calculation of the Number Needed to Treat ($NNT$), a crucial metric for evidence-based decision-making. By working through this scenario [@problem_id:4496933], you will practice synthesizing stratified risk data to evaluate the population-level impact of a prophylactic intervention, a skill essential for developing treatment guidelines and counseling patients.", "problem": "A maternal-fetal medicine team is counseling a cohort of pregnant kidney transplant recipients with stable allograft function about preventive strategies for hypertensive disorders of pregnancy. In the general obstetric population, the baseline absolute risk of preeclampsia is $0.045$. In kidney transplant recipients, the relative risk multiplier for preeclampsia attributable to the transplant status is $3.0$. Among these recipients, a proportion $p$ have preexisting chronic hypertension, where $p = 0.55$. For those with chronic hypertension, there is an additional multiplicative relative risk factor of $1.8$ beyond the transplant-associated relative risk; for those without chronic hypertension, there is no additional multiplicative factor beyond the transplant-associated relative risk. A policy of universal low-dose aspirin prophylaxis starting at $12$ weeks' gestation is considered; based on meta-analytic evidence, the relative risk multiplier for preeclampsia under aspirin prophylaxis is $0.85$ (assumed constant across strata).\n\nAssume the following:\n- Relative risks combine multiplicatively within a stratum.\n- The absolute risk in each stratum equals the general population baseline absolute risk multiplied by the applicable relative risk multipliers for that stratum.\n- The effect of aspirin prophylaxis is a constant multiplicative relative risk applied to the stratum-specific absolute risk.\n\nUnder these assumptions, compute the Number Needed to Treat with aspirin to prevent one case of preeclampsia in this kidney transplant pregnancy cohort. Report the final answer as a unitless number and round your answer to three significant figures.", "solution": "### Solution Derivation\nThe objective is to calculate the Number Needed to Treat (NNT). The NNT is the reciprocal of the Absolute Risk Reduction (ARR). The ARR, in turn, is the difference between the absolute risk in the untreated population ($AR_{untreated}$) and the absolute risk in the treated population ($AR_{treated}$).\n\n$$\nNNT = \\frac{1}{ARR} = \\frac{1}{AR_{untreated} - AR_{treated}}\n$$\n\nThe cohort of pregnant kidney transplant recipients is heterogeneous and can be divided into two strata:\n1.  Stratum 1: Recipients with preexisting chronic hypertension (cHTN). This group constitutes a proportion $p = 0.55$ of the cohort.\n2.  Stratum 2: Recipients without preexisting chronic hypertension (no cHTN). This group constitutes the remaining proportion, $1-p = 1 - 0.55 = 0.45$.\n\nFirst, we calculate the absolute risk of preeclampsia without aspirin prophylaxis ($AR_{untreated}$) for the entire cohort. This is the weighted average of the absolute risks of the two strata.\n\nFor Stratum 1 (with cHTN), the total relative risk, $RR_{1}$, is the product of the relative risk from the transplant and the additional relative risk from chronic hypertension.\n$$\nRR_{1} = RR_{tx} \\times RR_{cHTN} = 3.0 \\times 1.8 = 5.4\n$$\nThe absolute risk for this stratum, $AR_{1}$, is the baseline risk multiplied by this combined relative risk.\n$$\nAR_{1} = R_{base} \\times RR_{1} = 0.045 \\times 5.4 = 0.243\n$$\n\nFor Stratum 2 (no cHTN), the total relative risk, $RR_{2}$, is solely the relative risk from the transplant.\n$$\nRR_{2} = RR_{tx} = 3.0\n$$\nThe absolute risk for this stratum, $AR_{2}$, is:\n$$\nAR_{2} = R_{base} \\times RR_{2} = 0.045 \\times 3.0 = 0.135\n$$\n\nThe overall absolute risk for the entire cohort without treatment, $AR_{untreated}$, is the weighted average of the stratum-specific absolute risks.\n$$\nAR_{untreated} = (p \\times AR_{1}) + ((1 - p) \\times AR_{2})\n$$\nSubstituting the values:\n$$\nAR_{untreated} = (0.55 \\times 0.243) + (0.45 \\times 0.135)\n$$\n$$\nAR_{untreated} = 0.13365 + 0.06075 = 0.1944\n$$\nThis represents the absolute risk of preeclampsia in the cohort if no aspirin prophylaxis is given.\n\nNext, we calculate the absolute risk of preeclampsia with aspirin prophylaxis ($AR_{treated}$). The problem states that aspirin confers a relative risk multiplier of $RR_{ASA} = 0.85$. The absolute risk in the treated cohort is the untreated risk multiplied by this factor.\n$$\nAR_{treated} = AR_{untreated} \\times RR_{ASA}\n$$\n$$\nAR_{treated} = 0.1944 \\times 0.85 = 0.16524\n$$\n\nNow, we can calculate the Absolute Risk Reduction (ARR).\n$$\nARR = AR_{untreated} - AR_{treated}\n$$\n$$\nARR = 0.1944 - 0.16524 = 0.02916\n$$\nAlternatively, $ARR = AR_{untreated} \\times (1 - RR_{ASA}) = 0.1944 \\times (1 - 0.85) = 0.1944 \\times 0.15 = 0.02916$.\n\nFinally, the Number Needed to Treat (NNT) is the reciprocal of the ARR.\n$$\nNNT = \\frac{1}{ARR} = \\frac{1}{0.02916} \\approx 34.2935528...\n$$\n\nThe problem requires the answer to be rounded to three significant figures.\n$$\nNNT \\approx 34.3\n$$\nThis means that, on average, for every $34.3$ pregnant kidney transplant recipients treated with low-dose aspirin, one case of preeclampsia is prevented.", "answer": "$$\\boxed{34.3}$$", "id": "4496933"}, {"introduction": "The profound physiological changes of pregnancy significantly alter drug pharmacokinetics, necessitating careful dose adjustments for narrow therapeutic index drugs like tacrolimus. This practice guides you through a physiologically-based pharmacokinetic (PBPK) exercise using the well-stirred model of hepatic clearance, which integrates changes in blood flow, protein binding, and intrinsic metabolism. Mastering this type of calculation [@problem_id:4496912] moves beyond simple dose scaling and provides a mechanistic understanding of *why* doses must be changed, empowering you to make more informed and individualized therapeutic drug management decisions.", "problem": "A $30$-year-old gravida $1$, para $0$ patient with a well-functioning kidney allograft is maintained on immediate-release tacrolimus at a pre-pregnancy dose of $3$ mg every $12$ hours. Assume linear pharmacokinetics and that systemic elimination is entirely hepatic. You are asked to use a physiologically grounded model to determine the new per-dose tacrolimus amount needed during the second trimester to maintain the same average steady-state concentration as before pregnancy.\n\nUse the following fundamental base and assumptions:\n- Hepatic clearance follows the well-stirred model: $$CL_{h} \\;=\\; \\frac{Q_{h} \\, f_{u} \\, CL_{\\text{int}}}{Q_{h} + f_{u} \\, CL_{\\text{int}}},$$ where $Q_{h}$ is hepatic blood flow, $f_{u}$ is the fraction unbound in blood, and $CL_{\\text{int}}$ is intrinsic hepatic metabolic clearance.\n- Hepatic extraction ratio is $$E_{h} \\;=\\; \\frac{CL_{h}}{Q_{h}}, \\quad \\text{and hepatic availability is } F_{h} \\;=\\; 1 - E_{h}.$$\n- Oral bioavailability is the product of intestinal availability and hepatic availability: $$F \\;=\\; F_{g} \\, F_{h},$$ where $F_{g}$ is the fraction escaping intestinal first-pass.\n- Under linear kinetics at steady state, the Area Under the Curve (AUC) for one dosing interval $\\tau$ satisfies $$\\text{AUC} \\;=\\; \\frac{F \\, D}{CL},$$ and the average steady-state concentration is $$C_{\\text{avg,ss}} \\;=\\; \\frac{\\text{AUC}}{\\tau}.$$\n\nPre-pregnancy physiological and drug parameters:\n- Hepatic blood flow $Q_{h0} = 90$ L/h.\n- Fraction unbound $f_{u0} = \\frac{1}{100}$.\n- Intrinsic clearance $CL_{\\text{int},0} = \\frac{9000}{11}$ L/h.\n- Intestinal availability $F_{g0} = \\frac{3}{11}$.\n- Dosing interval $\\tau = 12$ h.\n- Per-dose amount $D_{0} = 3$ mg.\n\nSecond-trimester physiological changes to apply:\n- Hepatic blood flow increases by $25\\%$: $$Q_{h,\\text{preg}} = 1.25 \\, Q_{h0}.$$\n- Fraction unbound increases by $25\\%$: $$f_{u,\\text{preg}} = 1.25 \\, f_{u0}.$$\n- Intrinsic clearance increases by $30\\%$ (consistent with cytochrome P450 3A induction): $$CL_{\\text{int},\\text{preg}} = 1.30 \\, CL_{\\text{int},0}.$$\n- Intestinal availability decreases by $15\\%$ (consistent with increased intestinal metabolism/efflux): $$F_{g,\\text{preg}} = 0.85 \\, F_{g0}.$$\n\nAssume $CL = CL_{h}$ both pre-pregnancy and during pregnancy. Determine the new per-dose amount $D_{\\text{preg}}$ that will maintain the same $C_{\\text{avg,ss}}$ as pre-pregnancy. Round your final numerical answer to three significant figures. Express the dose per administration in mg. The final answer must be a single real number.", "solution": "### Solution Derivation\n\nThe objective is to find the dose during pregnancy, $D_{\\text{preg}}$, that maintains the average steady-state drug concentration, $C_{\\text{avg,ss}}$, at the pre-pregnancy level.\nThe average steady-state concentration is given by:\n$$C_{\\text{avg,ss}} = \\frac{\\text{AUC}}{\\tau} = \\frac{1}{\\tau} \\left( \\frac{F \\cdot D}{CL} \\right)$$\nThe condition to be met is $C_{\\text{avg,ss,preg}} = C_{\\text{avg,ss},0}$. Since the dosing interval $\\tau$ is constant, this simplifies to:\n$$ \\frac{F_{\\text{preg}} \\cdot D_{\\text{preg}}}{CL_{\\text{preg}}} = \\frac{F_{0} \\cdot D_{0}}{CL_{0}} $$\nSolving for the required dose during pregnancy, $D_{\\text{preg}}$:\n$$ D_{\\text{preg}} = D_{0} \\cdot \\left( \\frac{CL_{\\text{preg}}}{CL_{0}} \\right) \\cdot \\left( \\frac{F_{0}}{F_{\\text{preg}}} \\right) $$\nTo find $D_{\\text{preg}}$, we must first calculate the clearance ($CL_{0}, CL_{\\text{preg}}$) and bioavailability ($F_{0}, F_{\\text{preg}}$) for both the pre-pregnancy and pregnancy states.\n\n**1. Pre-pregnancy (Baseline) Calculations**\n\nFirst, calculate the product $f_{u0} \\cdot CL_{\\text{int},0}$:\n$$ f_{u0} \\cdot CL_{\\text{int},0} = \\frac{1}{100} \\cdot \\frac{9000}{11} \\, \\frac{\\text{L}}{\\text{h}} = \\frac{90}{11} \\, \\frac{\\text{L}}{\\text{h}} $$\nNow, calculate the pre-pregnancy hepatic clearance, $CL_{h0}$, which is equal to the total clearance $CL_0$:\n$$ CL_{0} = CL_{h0} = \\frac{Q_{h0} \\cdot (f_{u0} \\cdot CL_{\\text{int},0})}{Q_{h0} + (f_{u0} \\cdot CL_{\\text{int},0})} = \\frac{90 \\cdot \\frac{90}{11}}{90 + \\frac{90}{11}} = \\frac{\\frac{8100}{11}}{\\frac{990+90}{11}} = \\frac{8100}{1080} = 7.5 \\, \\frac{\\text{L}}{\\text{h}} = \\frac{15}{2} \\, \\frac{\\text{L}}{\\text{h}} $$\nNext, calculate the pre-pregnancy hepatic extraction ratio, $E_{h0}$, and hepatic availability, $F_{h0}$:\n$$ E_{h0} = \\frac{CL_{h0}}{Q_{h0}} = \\frac{7.5}{90} = \\frac{1}{12} $$\n$$ F_{h0} = 1 - E_{h0} = 1 - \\frac{1}{12} = \\frac{11}{12} $$\nFinally, calculate the pre-pregnancy oral bioavailability, $F_0$:\n$$ F_{0} = F_{g0} \\cdot F_{h0} = \\frac{3}{11} \\cdot \\frac{11}{12} = \\frac{3}{12} = \\frac{1}{4} $$\n\n**2. Second-Trimester (Pregnancy) Calculations**\n\nFirst, determine the new physiological and drug parameters for pregnancy:\n$$ Q_{h,\\text{preg}} = 1.25 \\cdot Q_{h0} = 1.25 \\cdot 90 = 112.5 \\, \\frac{\\text{L}}{\\text{h}} = \\frac{225}{2} \\, \\frac{\\text{L}}{\\text{h}} $$\n$$ f_{u,\\text{preg}} = 1.25 \\cdot f_{u0} = 1.25 \\cdot \\frac{1}{100} = \\frac{1.25}{100} = \\frac{1}{80} $$\n$$ CL_{\\text{int},\\text{preg}} = 1.30 \\cdot CL_{\\text{int},0} = 1.30 \\cdot \\frac{9000}{11} = \\frac{11700}{11} \\, \\frac{\\text{L}}{\\text{h}} $$\n$$ F_{g,\\text{preg}} = 0.85 \\cdot F_{g0} = 0.85 \\cdot \\frac{3}{11} = \\frac{17}{20} \\cdot \\frac{3}{11} = \\frac{51}{220} $$\nCalculate the product $f_{u,\\text{preg}} \\cdot CL_{\\text{int},\\text{preg}}$:\n$$ f_{u,\\text{preg}} \\cdot CL_{\\text{int},\\text{preg}} = \\frac{1}{80} \\cdot \\frac{11700}{11} = \\frac{1170}{88} = \\frac{585}{44} \\, \\frac{\\text{L}}{\\text{h}} $$\nNow, calculate the hepatic clearance during pregnancy, $CL_{\\text{preg}}$:\n$$ CL_{\\text{preg}} = \\frac{Q_{h,\\text{preg}} \\cdot (f_{u,\\text{preg}} \\cdot CL_{\\text{int},\\text{preg}})}{Q_{h,\\text{preg}} + (f_{u,\\text{preg}} \\cdot CL_{\\text{int},\\text{preg}})} = \\frac{\\frac{225}{2} \\cdot \\frac{585}{44}}{\\frac{225}{2} + \\frac{585}{44}} = \\frac{\\frac{131625}{88}}{\\frac{4950+585}{44}} = \\frac{\\frac{131625}{88}}{\\frac{5535}{44}} = \\frac{131625}{2 \\cdot 5535} = \\frac{131625}{11070} = \\frac{975}{82} \\, \\frac{\\text{L}}{\\text{h}} $$\nNext, calculate the hepatic extraction ratio, $E_{h, \\text{preg}}$, and hepatic availability, $F_{h, \\text{preg}}$:\n$$ E_{h, \\text{preg}} = \\frac{CL_{\\text{preg}}}{Q_{h,\\text{preg}}} = \\frac{975/82}{225/2} = \\frac{975 \\cdot 2}{82 \\cdot 225} = \\frac{1950}{18450} = \\frac{195}{1845} = \\frac{13}{123} $$\n$$ F_{h,\\text{preg}} = 1 - E_{h, \\text{preg}} = 1 - \\frac{13}{123} = \\frac{110}{123} $$\nFinally, calculate the oral bioavailability during pregnancy, $F_{\\text{preg}}$:\n$$ F_{\\text{preg}} = F_{g,\\text{preg}} \\cdot F_{h,\\text{preg}} = \\frac{51}{220} \\cdot \\frac{110}{123} = \\frac{51}{2 \\cdot 123} = \\frac{3 \\cdot 17}{2 \\cdot 3 \\cdot 41} = \\frac{17}{82} $$\n\n**3. Final Dose Calculation**\n\nNow substitute the calculated values for clearances and bioavailabilities into the dose adjustment equation:\n$$ D_{\\text{preg}} = D_{0} \\cdot \\left( \\frac{CL_{\\text{preg}}}{CL_{0}} \\right) \\cdot \\left( \\frac{F_{0}}{F_{\\text{preg}}} \\right) $$\n$$ D_{\\text{preg}} = (3 \\, \\text{mg}) \\cdot \\left( \\frac{975/82}{15/2} \\right) \\cdot \\left( \\frac{1/4}{17/82} \\right) $$\n$$ D_{\\text{preg}} = 3 \\cdot \\left( \\frac{975 \\cdot 2}{82 \\cdot 15} \\right) \\cdot \\left( \\frac{1 \\cdot 82}{4 \\cdot 17} \\right) $$\nThe term $82$ in the numerator and denominator cancels out:\n$$ D_{\\text{preg}} = 3 \\cdot \\frac{975 \\cdot 2}{15 \\cdot 4 \\cdot 17} = 3 \\cdot \\frac{1950}{1020} = 3 \\cdot \\frac{195}{102} $$\nSimplifying the fraction:\n$$ D_{\\text{preg}} = 3 \\cdot \\frac{3 \\cdot 65}{3 \\cdot 34} = 3 \\cdot \\frac{65}{34} = \\frac{195}{34} \\, \\text{mg} $$\nNow, we compute the numerical value:\n$$ D_{\\text{preg}} \\approx 5.735294... \\, \\text{mg} $$\nRounding to three significant figures as requested:\n$$ D_{\\text{preg}} \\approx 5.74 \\, \\text{mg} $$", "answer": "$$\\boxed{5.74}$$", "id": "4496912"}, {"introduction": "Following delivery, a key concern for transplant recipients is the safety of breastfeeding while on essential immunosuppressive medications. This problem focuses on calculating the Relative Infant Dose ($RID$), the gold standard for assessing infant drug exposure through milk. The calculation is based on fundamental principles including plasma protein binding and pH-partitioning, which can cause \"ion trapping\" of weak bases in the relatively acidic environment of milk. By completing this exercise [@problem_id:4496916], you will gain practical skills in estimating neonatal risk, enabling you to provide evidence-based guidance to postpartum patients.", "problem": "A postpartum patient with a history of kidney transplantation wishes to exclusively breastfeed. She is receiving an immediate-release calcineurin inhibitor that behaves as a weak base in physiological fluids. Assume the following scientifically grounded principles: (i) passive transmembrane flux is governed by Fick’s law, (ii) only the unbound and unionized drug partitions across the lipid membrane, (iii) at steady state the unbound, unionized concentration is equal in plasma and in the aqueous phase of milk, and (iv) ionization is governed by the Henderson–Hasselbalch relationship for weak bases. Neglect active transport, metabolism within the mammary gland, and any partitioning into the lipid fraction beyond what is implicit in the provided unbound fractions.\n\nData:\n- Maternal steady-state total plasma concentration of the drug: $C_{p,\\mathrm{tot}} = 8 \\ \\text{ng/mL}$.\n- Drug acid dissociation constant: $\\mathrm{p}K_{a} = 7.7$ (weak base).\n- Plasma $\\mathrm{pH}$: $7.4$; milk aqueous-phase $\\mathrm{pH}$: $7.0$.\n- Unbound fraction in plasma: $f_{u,p} = 0.02$; unbound fraction in milk aqueous phase: $f_{u,m} = 0.40$.\n- Maternal dosing regimen: $3 \\ \\text{mg}$ twice daily (total daily dose $= 6 \\ \\text{mg/day}$).\n- Maternal body mass: $65 \\ \\text{kg}$.\n- Infant daily milk intake: $150 \\ \\text{mL/kg/day}$.\n\nUsing only the principles stated above and standard unit conversions, compute the relative infant dose (RID), defined as the ratio of the infant’s ingested daily dose per kilogram to the maternal daily dose per kilogram. Express the RID as a unitless decimal. Round your final answer to three significant figures.", "solution": "The objective is to compute the Relative Infant Dose (RID), which is defined as the ratio of the infant's weight-normalized daily dose to the mother's weight-normalized daily dose.\n$$\n\\text{RID} = \\frac{\\text{Infant Dose per kg}}{\\text{Maternal Dose per kg}} = \\frac{D'_{inf}}{D'_{mat}}\n$$\nFirst, we calculate the maternal dose per kilogram, $D'_{mat}$. The total daily maternal dose is $D_{mat, daily} = 2 \\times 3 \\ \\text{mg/day} = 6 \\ \\text{mg/day}$. The maternal body mass is $M_{mat} = 65 \\ \\text{kg}$.\nTo ensure consistent units, we convert milligrams ($mg$) to nanograms ($ng$): $1 \\ \\text{mg} = 10^6 \\ \\text{ng}$.\n$$\nD'_{mat} = \\frac{D_{mat, daily}}{M_{mat}} = \\frac{6 \\times 10^6 \\ \\text{ng/day}}{65 \\ \\text{kg}}\n$$\nNext, we calculate the infant dose per kilogram, $D'_{inf}$. This is the product of the total drug concentration in milk, $C_m$, and the infant's normalized daily milk intake, $I_{inf, norm} = 150 \\ \\text{mL/kg/day}$.\n$$\nD'_{inf} = C_m \\times I_{inf, norm}\n$$\nTo find $C_m$, we must model the drug partitioning from plasma to milk based on the provided principles.\n\nPrinciple (ii) states that only the unbound and unionized form of the drug can cross the membrane. Principle (iii) states that at steady state, the concentration of this form is equal in both compartments:\n$$\nC_{p,uu} = C_{m,uu}\n$$\nwhere $C_{p,uu}$ is the unbound, unionized concentration in plasma and $C_{m,uu}$ is the unbound, unionized concentration in the aqueous phase of milk.\n\nThe unbound, unionized concentration in plasma, $C_{p,uu}$, is related to the total plasma concentration, $C_{p,\\mathrm{tot}}$, by the unbound fraction in plasma, $f_{u,p}$, and the fraction of unbound drug that is unionized in plasma, $\\alpha_{u,p}$.\n$$\nC_{p,uu} = C_{p,\\mathrm{tot}} \\times f_{u,p} \\times \\alpha_{u,p}\n$$\nThe fraction unionized, $\\alpha_{u,p}$, is determined by the Henderson-Hasselbalch equation for a weak base (Principle iv):\n$$\n\\mathrm{pH} = \\mathrm{p}K_a + \\log\\left(\\frac{[\\text{B}]}{[\\text{BH}^+]}\\right)\n$$\nwhere $[\\text{B}]$ is the concentration of the unionized base and $[\\text{BH}^+]$ is the concentration of the ionized conjugate acid. The fraction unionized, $\\alpha_u$, is given by:\n$$\n\\alpha_u = \\frac{[\\text{B}]}{[\\text{B}] + [\\text{BH}^+]} = \\frac{1}{1 + \\frac{[\\text{BH}^+]}{[\\text{B}]}}\n$$\nFrom the Henderson-Hasselbalch equation, $\\frac{[\\text{BH}^+]}{[\\text{B}]} = 10^{\\mathrm{p}K_a - \\mathrm{pH}}$. Thus, the fraction unionized in plasma is:\n$$\n\\alpha_{u,p} = \\frac{1}{1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_p}}\n$$\nSimilarly, the total concentration in milk, $C_m$, is related to the unbound, unionized concentration in milk, $C_{m,uu}$, by the unbound fraction in milk, $f_{u,m}$, and the fraction unionized in milk, $\\alpha_{u,m}$:\n$$\nC_{m,uu} = C_m \\times f_{u,m} \\times \\alpha_{u,m}\n$$\nwhere\n$$\n\\alpha_{u,m} = \\frac{1}{1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_m}}\n$$\nBy equating $C_{p,uu} = C_{m,uu}$, we get:\n$$\nC_{p,\\mathrm{tot}} \\times f_{u,p} \\times \\alpha_{u,p} = C_m \\times f_{u,m} \\times \\alpha_{u,m}\n$$\nRearranging for the milk-to-plasma ratio ($C_m/C_{p,\\mathrm{tot}}$):\n$$\n\\frac{C_m}{C_{p,\\mathrm{tot}}} = \\frac{f_{u,p}}{f_{u,m}} \\frac{\\alpha_{u,p}}{\\alpha_{u,m}} = \\frac{f_{u,p}}{f_{u,m}} \\frac{1/(1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_p})}{1/(1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_m})} = \\frac{f_{u,p}}{f_{u,m}} \\frac{1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_m}}{1 + 10^{\\mathrm{p}K_a - \\mathrm{pH}_p}}\n$$\nNow, we substitute the given values: $f_{u,p} = 0.02$, $f_{u,m} = 0.40$, $\\mathrm{p}K_a = 7.7$, $\\mathrm{pH}_p = 7.4$, and $\\mathrm{pH}_m = 7.0$.\n$$\n\\frac{C_m}{C_{p,\\mathrm{tot}}} = \\frac{0.02}{0.40} \\times \\frac{1 + 10^{7.7 - 7.0}}{1 + 10^{7.7 - 7.4}} = 0.05 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}}\n$$\nThe total concentration in milk, $C_m$, can now be calculated using $C_{p,\\mathrm{tot}} = 8 \\ \\text{ng/mL}$:\n$$\nC_m = 8 \\times 0.05 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}} \\ \\text{ng/mL} = 0.4 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}} \\ \\text{ng/mL}\n$$\nNow we compute the infant dose per kg:\n$$\nD'_{inf} = C_m \\times I_{inf, norm} = \\left(0.4 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}}\\right) \\frac{\\text{ng}}{\\text{mL}} \\times 150 \\ \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{day}} = 60 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}} \\ \\frac{\\text{ng}}{\\text{kg} \\cdot \\text{day}}\n$$\nFinally, we compute the RID by taking the ratio of $D'_{inf}$ and $D'_{mat}$:\n$$\n\\text{RID} = \\frac{D'_{inf}}{D'_{mat}} = \\frac{60 \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}} \\ \\frac{\\text{ng}}{\\text{kg} \\cdot \\text{day}}}{\\frac{6 \\times 10^6}{65} \\ \\frac{\\text{ng}}{\\text{kg} \\cdot \\text{day}}} = \\frac{60 \\times 65}{6 \\times 10^6} \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}}\n$$\n$$\n\\text{RID} = \\frac{3900}{6 \\times 10^6} \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}} = 6.5 \\times 10^{-4} \\times \\frac{1 + 10^{0.7}}{1 + 10^{0.3}}\n$$\nCalculating the numerical value:\n$$\n\\text{RID} \\approx 6.5 \\times 10^{-4} \\times \\frac{1 + 5.01187}{1 + 1.99526} \\approx 6.5 \\times 10^{-4} \\times \\frac{6.01187}{2.99526} \\approx 6.5 \\times 10^{-4} \\times 2.007127\n$$\n$$\n\\text{RID} \\approx 0.00130463\n$$\nRounding to three significant figures, we get $0.00130$. In scientific notation, this is $1.30 \\times 10^{-3}$.", "answer": "$$\n\\boxed{1.30 \\times 10^{-3}}\n$$", "id": "4496916"}]}